These results reveal a combination of high SENP1 and HIF2α expression gives particularly poor prognosis for ccRCC patients and suggest that SENP1 may be an attractive new target for treating metastatic RCC (mRCC). The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.